Clinical Report: Evaluation of Bone Marrow Hemodilution Impact on MRD in MM
Overview
This review discusses the significant impact of bone marrow hemodilution on the assessment of measurable residual disease (MRD) in multiple myeloma (MM) using next generation flow cytometry (NGF). It highlights the potential for false negative outcomes due to hemodilution and the need for standardized evaluation methods.
Background
Multiple myeloma is a prevalent hematological malignancy characterized by clonal plasma cell proliferation in the bone marrow. Accurate assessment of measurable residual disease (MRD) is crucial as MRD negativity correlates with improved patient outcomes. However, hemodilution during bone marrow aspiration can compromise MRD evaluations, leading to false negatives and impacting treatment decisions.
Data Highlights
No numerical data provided in the article.
Key Findings
Bone marrow hemodilution can significantly distort MRD assessments in multiple myeloma.
Next Generation Flow Cytometry (NGF) is preferred for MRD identification due to its cost-effectiveness and ability to evaluate hemodilution.
Hemodilution may reduce the representation of clonal plasma cells, leading to false negative results.
Various organizations propose different adequacy markers for assessing hemodilution, indicating a lack of standardization.
Multiparametric approaches using mast cells, nucleated red blood cells, and B cell progenitors may enhance hemodilution evaluation reliability.
Clinical Implications
Clinicians should be aware of the potential for hemodilution to affect MRD assessments in multiple myeloma, particularly when interpreting results from bone marrow aspirates. Standardized methods for evaluating hemodilution are needed to improve the accuracy of MRD evaluations and inform treatment strategies.
Conclusion
The review underscores the critical need for standardized approaches to assess hemodilution in multiple myeloma to avoid false negative MRD results, which can significantly impact patient management.
